Ensysce Biosciences wins Nasdaq stockholders’ equity compliance, still faces delisting risk if next filing falls short

• Nasdaq warned Ensysce it faces delisting if its next SEC periodic report fails to show compliance with the $2.5 million stockholders’ equity rule.
• Nasdaq granted an extension to regain the $1 minimum bid-price requirement, setting a new deadline of Feb. 22, 2027.
• Nasdaq classified the Cy Biopharma acquisition as a change of control, triggering an initial listing review before shareholder approval of preferred conversion.
• Failure to meet initial listing standards could lead to a trading suspension, with an initial listing application planned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-040080), on August 25, 2026, and is solely responsible for the information contained therein.